US Patent Issued to MEDIVIR on May 20 for "Methods for treating liver cancers using an orally administered dioxolane nucleotide in combination with an anti-PD1 or anti-PDL1 monoclonal antibody" (Swedish Inventor)

ALEXANDRIA, Va., June 16 -- United States Patent no. 12,303,521, issued on May 20, was assigned to MEDIVIR AB (Stockholm).

"Methods for treating liver cancers using an orally administered dioxolane nucleotide in combination with an anti-PD1 or anti-PDL1 monoclonal antibody" was invented by Mark Albertella (Huddinge, Sweden).

According to the abstract* released by the U.S. Patent & Trademark Office: "Use of a compound of the formula I: or a pharmaceutically acceptable salt thereof, in the therapy of a liver cancer in a mammal, characterized by the concurrent or sequential treatment of the mammal with a monoclonal antibody which blocks the binding of PD-L1 and/or PD-L2 to PD-1."

The patent was filed on Feb. 17, 2020, under Application No. ...